Longeveron (LGVN) Common Equity (2020 - 2026)
Longeveron (LGVN) posted quarterly Common Equity of $16.0 million for Q1 2026, down 6.59% year-over-year from $17.2 million in Q1 2025, and up 182.41% quarter-over-quarter from $5.7 million in Q4 2025.
Longeveron (LGVN) Common Equity (2020 - 2026) Analysis & Trends
Longeveron's Common Equity history runs 7 years deep, the most recent figure standing at $16.0 million for Q1 2026.
- In Q1 2026, Common Equity fell 6.59% year-over-year to $16.0 million; the TTM figure through Mar 2026 stood at $16.0 million (down 6.59% YoY), while the FY2025 annual figure was $5.7 million, down 74.07% from the prior year.
- Common Equity for Q1 2026 stood at $16.0 million, up from $5.7 million in the prior quarter.
- The five-year high for Common Equity was $34.3 million in Q1 2022, with the low at $3.0 million in Q1 2024.
- The 5-year median for Common Equity is $16.0 million (2026), against an average of $16.3 million.
- The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 81.36% in 2024, then jumped 464.22% in 2025.
- Longeveron's Common Equity stood at $20.5 million in 2022, then tumbled by 67.12% to $6.7 million in 2023, then surged by 224.68% to $21.9 million in 2024, then tumbled by 74.07% to $5.7 million in 2025, then surged by 182.41% to $16.0 million in 2026.
- Business Quant data shows LGVN's Common Equity at $16.0 million in Q1 2026, $5.7 million in Q4 2025, and $10.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 10.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.40 Mn |
| Mar 31, 2026 | 16.03 Mn |
| Dec 31, 2025 | 5.68 Mn |
| Sep 30, 2025 | 9.97 Mn |
| Jun 30, 2025 | 12.66 Mn |
| Mar 31, 2025 | 17.16 Mn |
| Dec 31, 2024 | 21.89 Mn |
| Sep 30, 2024 | 25.63 Mn |
| Jun 30, 2024 | 14.91 Mn |
| Mar 31, 2024 | 3.04 Mn |
| Dec 31, 2023 | 6.74 Mn |
| Sep 30, 2023 | 6.63 Mn |
| Jun 30, 2023 | 11.26 Mn |
| Mar 31, 2023 | 16.32 Mn |
| Dec 31, 2022 | 20.50 Mn |
| Sep 30, 2022 | 24.62 Mn |
| Jun 30, 2022 | 29.38 Mn |
| Mar 31, 2022 | 34.31 Mn |
| Dec 31, 2021 | 37.45 Mn |
| Dec 31, 2020 | 1.96 Mn |